

New Directions in the Diagnosis and Treatment of Hematologic Cancers

APRIL 16, 2024

Hematologic malignancies research is growing at a rapid pace, increasing the complexity of the field. Advances in the understanding of the mechanisms of hematologic malignancies have resulted in the development of new prognostic models, novel therapies, and improvements in disease management. It is essential to our community to stay abreast of the latest findings in the field and of their potential impact on clinical practices.

This symposium will provide attendees with cutting-edge updates and perspectives on new diagnostic tools and management options of hematologic malignancies including genetic profiling, cytogenetics, molecular diagnostics, risk-adaptive strategies, and novel therapies recently approved by the FDA. Advances in the understanding of aggressive/indolent lymphoma, myelodysplasia, plasma cell dyscrasia, acute/chronic leukemia, and myeloproliferative disease will be addressed. Newer therapeutic approaches in classical hematology will also be reviewed.


PROGRAM DIRECTOR



Rashmi Khanal, MD

Assistant Professor,
Department of Bone Marrow Transplant
and Cellular Therapies

FACULTY



Henry Fung, MD, FACP, FRCPE

Chair and Professor, Department of Bone Marrow Transplant and Cellular Therapies

Zachary Frosch, MD, MSHP

Assistant Professor, Department of Hematology/Oncology

Marcus Messmer, MD

Assistant Professor, Department of Hematology/Oncology

Iberia Romina Sosa, MD, PhD

Chief, Division of Hematology; Associate Professor, Department of Hematology/Oncology

Michael Jay Styler, MD

Associate Professor, Department of Bone Marrow Transplant and Cellular Therapies

Asya Nina Varshavsky-Yanovsky, MD, PhD

Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies

REGISTER TODAY: FoxChase.org/CME

DATE AND TIMES: Tuesday, April 16, 2024

5:45 – 7:00 PM EST Check-in & Reception
(Buffet opens at 6:30)

7:00 – 9:00 PM EST CME & Dinner

LOCATION: Philadelphia Marriott Old City
One Dock Street | Philadelphia, PA 19106

INQUIRIES: Lucía Tono, PhD, MEd | 215-728-3797
Lucia.Tono-Ramirez@tuhs.temple.edu

REGISTRATION:



LEARNING OBJECTIVES

After participating in this educational program, learners should be able to:

- Summarize the findings from key clinical trials presented at the 2023 ASH meeting that will impact standards of care in hematology
- Discuss the latest findings in genetic profiling, cytogenetics, and molecular biology, and describe how this information can be utilized in determining patient prognosis and treatment course
- List novel, targeted therapies in development for hematology and explain the therapeutic rationale for these agents
- Describe the latest advances in the field of classical hematology that will impact patient treatment
- Outline the ways clinical trial data can be efficiently incorporated into community-based hematology practice

INTENDED AUDIENCE

The program is designed for oncologists, hematologists, radiation oncologists, pathologists, internists, primary care physicians, fellows, physician assistants, nurse practitioners, oncology nurses, and social workers.

ACCREDITATION STATEMENT

The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of **2 AMA PRA Category 1 Credits™**. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.